Clinical trials · New York
Relapsed/Refractory Multiple Myeloma clinical trials in New York
We’re tracking 16 recruiting relapsed/refractory multiple myeloma studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
New York, New YorkAges 18 years+ - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Buffalo, New YorkAges 18 years+ - NCT07284758RecruitingPhase 2
Cemsidomide and dexamethasone for relapsed/refractory multiple myeloma
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
New York, New YorkAges 18 years+ - NCT07222761RecruitingPhase 3
Comparing new treatments for relapsed multiple myeloma
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
New York, New YorkAges 18 years+ - NCT07280013RecruitingPhase 1
Cemsidomide with elranatamab for multiple myeloma
This trial tests a new drug combination (cemsidomide and elranatamab) for people with multiple myeloma that has come back after previous treatments. The goal is to see if the combination is safe and works better than current options.
Brooklyn, New YorkAges 18 years+ - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
New York, New YorkAges 18 years+ - NCT05722418RecruitingPhase 1
CRISPR-edited CAR-T for harder-to-treat myeloma
This Phase 1 study tests a lab-made immune cell therapy (CAR-T) made from a donor, with a CRISPR edit, for multiple myeloma that has come back or not responded to treatment. It aims to find the safest way to give the treatment and see how well it can control the cancer.
New York, New YorkAges 18 years+ - NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Stony Brook, New YorkAges 18 years+ - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
The Bronx, New YorkAges 18 years+ - NCT06896916RecruitingPhase 1
Study of etentamig and a CELMoD drug for relapsed multiple myeloma
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
New York, New YorkAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
New York, New YorkAges 18 years+ - NCT02343042RecruitingPhase 1/Phase 2
Selinexor with standard therapies for multiple myeloma
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
New York, New YorkAges 18 years+ - NCT06153251RecruitingPhase 1
Study of BMS-986453 for Relapsed or Refractory Multiple Myeloma
This study tests a new drug, BMS-986453, for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if it is safe and works against the cancer.
New York, New YorkAges 18 years+ - NCT06827860RecruitingPhase 2
Talquetamab shot for elderly with relapsed multiple myeloma
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
New York, New YorkAges 70 years+ - NCT05623020RecruitingPhase 3
New treatment for newly diagnosed transplant-ineligible myeloma
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
Commack, New YorkAges 18 years+ - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Buffalo, New YorkAges 12 years+
Relapsed/Refractory Multiple Myeloma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting relapsed/refractory multiple myeloma studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Icahn School of Medicine at Mount Sinai · 4 studies
- Weill Cornell Medicine · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Montefiore Medical Center · 2 studies
- Mount Sinai Health System · 2 studies
- Memorial Sloan Kettering Cancer Center - Westchester
- Memorial Sloan Kettering Nassau
What taking part in a relapsed/refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Relapsed/Refractory Multiple Myeloma trials in other states
Common questions
- Are there relapsed/refractory multiple myeloma clinical trials in New York?
- Yes. We're currently tracking 16 recruiting relapsed/refractory multiple myeloma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed/refractory multiple myeloma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed/refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed/refractory multiple myeloma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.